Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-24-006563
Filing Date
2024-05-02
Accepted
2024-05-02 16:43:51
Documents
109
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bpmc-20240331x10q.htm   iXBRL 10-Q 2388887
2 EX-10.1 bpmc-20240331xex10d1.htm EX-10.1 35769
3 EX-31.1 bpmc-20240331xex31d1.htm EX-31.1 11333
4 EX-31.2 bpmc-20240331xex31d2.htm EX-31.2 11404
5 EX-32.1 bpmc-20240331xex32d1.htm EX-32.1 10864
  Complete submission text file 0001558370-24-006563.txt   10300420

Data Files

Seq Description Document Type Size
6 EX-101.SCH bpmc-20240331.xsd EX-101.SCH 83599
7 EX-101.CAL bpmc-20240331_cal.xml EX-101.CAL 73405
8 EX-101.DEF bpmc-20240331_def.xml EX-101.DEF 338563
9 EX-101.LAB bpmc-20240331_lab.xml EX-101.LAB 639305
10 EX-101.PRE bpmc-20240331_pre.xml EX-101.PRE 574665
113 EXTRACTED XBRL INSTANCE DOCUMENT bpmc-20240331x10q_htm.xml XML 1716098
Mailing Address 45 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 45 SIDNEY STREET CAMBRIDGE MA 02139 617-374-7580
Blueprint Medicines Corp (Filer) CIK: 0001597264 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37359 | Film No.: 24909241
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)